

IMI2 - Call 15 webinar: Antimicrobial Resistance Accelerator - Pillars A (Capability Building Network) and B (Tuberculosis Drug Development Network)



| First Name | Last Name | Email | Country | Organization | Briefly, what would you bring to the project in terms of expertise, resources, activities? |
|------------|----------------|-------------------------------------|---------------|---|--|
| Anett | Pfeiffer | a.pfeiffer@eurice.eu | Germany | EURICE GmbH | Expertise in collaborative project management and exploitation management (management partner in running IMI projects) |
| Alexander | Berg | aberg@c-path.org | United States | Critical Path Institute | C-Path's CPTR initiative has expertise in clinical trial data aggregation/curation and advancing drug development tools for TB |
| Amanda | Borens | aborens@c-path.org | United States | Critical Path Institute | I have twenty years of healthcare and life science informatics experience, especially related to managing big data |
| Markus | Pasterk | admin.dir@bbmri-eric.eu | Austria | BBMRI-ERIC | |
| Jose | Ainsa | ainsa@unizar.es | Spain | UZ | Expertise and resources, more than 20 years experience in drug resistance and drug development in tuberculosis |
| Ameeta | Parekh | ameeta.parekh@fda.hhs.gov | United States | FDA CDER | |
| Amélie | Abrantes | amelie.abrantes@u-bordeaux.fr | France | Université de Bordeaux | |
| Anandi | Martin | anandi.martin@uclouvain.be | Belgium | Université catholique de Louvain (UCL) | Expert in Tuberculosis and drug testing with REMA platform and molecular platform |
| Angelo | Iacobino | angelo.iacobino@iss.it | Italy | Istituto Superiore di Sanità | |
| Aniek | Doensen | aniek.doensen@catalyze.nl | Netherlands | Catalyze | |
| Annelies | van Ravestijn | Annelies.vanravestijn@radboudumc.nl | Netherlands | Radboudumc | |
| Astrid | Flandorfer | astrid.flandorfer@ffg.at | Austria | FFG | |
| Aurelien | Chollet | aurelien.chollet@antabio.com | France | Antabio SAS | Antabio is a SME dedicated to the R&D of innovative programs to tackle the antimicrobial resistance. We have two lead programs |
| Adrianne | Wong | awong@iavi.org | United States | IAVI | |
| Sharee | Basdeo | basdeos@tcd.ie | Ireland | Trinity Translational Medicine Institute | |
| Bernhard | Kerscher | bernhard.kerscher@pei.de | Germany | Paul-Ehrlich-Institut, Division of Microbiology | We provide a wealth of regulatory experience (scientific advice; quality-, pre-clinical- & clinical data analysis; vaccinology). |
| Carlos | Diaz | cdiaz@synapse-managers.com | Spain | SYNAPSE RESEARCH MANAGEMENT PARTNERS, S.L. | Project Management |
| Célia | Cabral | celia.cabral@fmed.uc.pt | Portugal | Faculdade de Medicina, Universidade de Coimbra | |
| claus stie | kallesøe | claus@grit42.com | Denmark | grit42 | Software for the data management. Building on the work we did in IMI ND4BB Translocation |
| Carl | Nathan | cnathan@med.cornell.edu | United States | Weill Cornell Medicine | TBDA member, TBRU PI |
| Concepción | González-Bello | concepcion.gonzalez.bello@usc.es | Spain | Universidade de Santiago de Compostela, CIQUS | novel targets, synthesis, structure-based design, irreversible inhibitors, MD simulations, crystallization enzyme/inhibitor |
| Corentin | Chaboud | corentin.chaboud@bioaster.org | France | BIOASTER | animal models of infection, data management & analysis (omics, microbiology & clinical data), PK/PD evaluation |

| | | | | | |
|-----------|------------------|---------------------------------------|----------------|--|---|
| István | Csizmadia | csizmadia.istvan@aek.hu | Hungary | National Health Service Center (ÁEEK) | 100 Public hospitals, Data Management, Operating national Electronic Health Cooperation Service Space (EESZT), Patient engagement |
| Doris | Rakoczy | doris.rakoczy@ait.ac.at | Austria | AIT Austrian Institute of Technology GmbH | |
| Elena | del Rey | edelrey@synapse-managers.com | Spain | SYNAPSE RESEARCH MANAGEMENT PARTNERS, S.L. | Project Management |
| Edita | Bagdonaite | edita.bagdonaite@mita.lt | Lithuania | Agency for Science, Innovation and Technology | |
| Elisa | Vergari | elisa.vergari@ec.europa.eu | Belgium | ERCEA | Scientific Expertise having a PhD in Physiology |
| Ezequiel | Mas del Molino | ezequiel.masdelmolino@bsc.es | Spain | Barcelona Supercomputing Center | Supercomputing and Biomedical expertise |
| Federico | Giannoni | federico.giannoni@iss.it | Italy | Istituto Superiore di Sanità | Our group is expert on testing drugs and drug combinations in different Mtb growth conditions, and on studies of persistence |
| florence | Chung | florence.chung@inserm-transfert.fr | France | Inserm Transfert | |
| Francisco | Abad-Santos | francisco.abad@salud.madrid.org | Spain | Hospital Universitario de la Princesa | first in human clinical trials |
| Giulia | MANINA | giulia.manina@pasteur.fr | France | Pasteur Institute, Paris | Original approaches for TB-drug discovery. |
| Graham | Somers | graham.i.somers@gsk.com | United Kingdom | GSK | |
| Greg | Basarab | greg.basarab@uct.ac.za | South Africa | University of Cape Town, Drug Discovery and Development Centre (UCT/H3D) | Drug discovery research in tuberculosis, malaria and other infectious diseases. TB screening capabilities; DMPK and MedChem |
| ITZIAR | ACHA | iacha@bioef.org | Spain | Fundación Vasca de Innovación e Investigación Sanitarias - BIOEF | |
| Isabelle | Bekeredjian-Ding | isabelle.bekeredjian-ding@pei.de | Germany | Paul-Ehrlich-Institut | We have regulatory expertise for vaccines and mAb in clinical trials, preclinical and biostatistics as well as animal models |
| Jurriaan | de Steenwinkel | j.desteenwinkel@erasmusmc.nl | Netherlands | Erasmus MC | Preclinical assays to test in vitro, ex vivo and in vivo activity of new drugs |
| Joanna | Bacon | joanna.bacon@phe.gov.uk | United Kingdom | TB Research Group, Public Health England, Porton Down, Salisbury, UK | PHE has rare in vitro and in vivo models for the evaluation of antimycobacterials and for research into AMR and drug tolerance |
| Jonathan | Gomez-Raja | jonathan.gomez@fundesalud.es | Spain | FundeSalud, Government of Extremadura | Hospitals (14), patients and expertise in infectious diseases and EU projects |
| José Luis | Narro | jose.luis.narro@idipaz.es | Spain | FIBHULP-IdiPAZ | Experience in Clinical Trials and Studies and in Infectious Diseases, including TB, research and clinical management, |
| Juan | Riese | jriese@eu-isciii.es | Spain | National Health Institute 'Carlos III' | Eols from potential researchers that are willing to participate in the present call topic |
| Juan José | Vaquero | juanjose.vaquero@uc3m.es | Spain | Universidad Carlos III de Madrid | Quantitative imaging capabilities, methods, tools and resources for in vitro, in vivo and clinical imaging. |
| Julio | Mancera | julio.mancera@cloverbiosoft.com | Spain | Clover Biosoft | Wide experience in MS MALD-TOF and bioinformatics |
| Katja | Boelcker | k.boelcker@european-biotechnology.net | Germany | Biocom AG | Communication, dissemination, project management for EU, IMI and national programmes, conference planning |
| Laura | Griestop | l.griestop@european-biotechnology.net | Germany | BIOCOM AG | |
| Lanfranco | Fattorini | lanfranco.fattorini@iss.it | Italy | Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy | Drug activity against replicating & dormant M. tuberculosis by Wayne models (hypoxia at pH 5.8, 6.6 and 7.3 (mimicking caseum)) |

| | | | | | |
|---------------|------------------|-----------------------------------|----------------|---|--|
| LARISA | MIHOREANU | larisa.mihoreanu@anm.ro | Romania | ANMDM | In Romania, we are working on expanding the list of medicines to treat TBC -designated as national priority. |
| Laura | Barreales | laura.barreales@salud.madrid.org | Spain | IRYCIS | Management of European projects |
| Laura | Cendron | laura.cendron@unipd.it | Italy | University of Padova | Expertise in: structural biology, biochemistry and protein-drugs interaction; beta-lactamases, SOS-response pathway |
| Anne | Lenaerts | lenaerts@colostate.edu | United States | Colorado State University | We are involved in preclinical testing of TB drugs, with a research focus on animal models of TB infection |
| Lindsay | Lehmann | llehmann@c-path.org | United States | Critical Path Institute | C-Path's CPTR initiative has an active and maintained data platform for sharing of clinical trial data in TB clinical trials. |
| Michela | Tacca | m.tacca@uke.de | Germany | University Medical Centre Hamburg-Eppendorf | |
| Marco | pieron | marco.pieron@unipr.it | Italy | University of Parma | I am TB medicinal chemist |
| Cristina | Velasco | mariacristina.velasco@uc3m.es | Spain | Universidad Carlos III de Madrid | Management of the project |
| Maria Rosalia | Pasca | mariarosalia.pasca@unipv.it | Italy | University of Pavia | I participated to NM4TB-MM4TB clusters and my research topic is the study of the mechanism of action of new anti-TB compounds |
| Marit | Holleman | marit.holleman@tbvi.eu | Netherlands | Tuberculosis Vaccine Initiative (TBVI) | Expertise in coordination of a European consortium in the field of tuberculosis vaccine discovery and translational research. |
| Martha | Brumfield | mbrumfield@c-path.org | United States | Critical Path Institute | C-Path's CPTR initiative has an active and maintained data platform for sharing of clinical trial data in TB clinical trials |
| Mireia | Gimenez | mgimenez@leitat.org | Spain | LEITAT | Extensive preclinical models; in depth mechanism of action investigation; biodistribution; organoid technology; Biosensors; NPs. |
| Alex | Mira | mira_ale@gva.es | Spain | FISABIO Foundation | In vitro model to measure antibiotic susceptibility of biofilm infections |
| Iain | Old | mm4tb@rocketmail.com | United Kingdom | nim4tb | 12 years of managing FP5,6,7 Tuberculosis drug discovery projects |
| Bruno | Mourenza | mourenza@apre.it | Italy | APRE | |
| Marco | Schito | mschito@c-path.org | United States | Critical Path Institute | Data sharing platform efforts and integration with AMR diagnostic initiatives |
| Neeraj | Dhar | neeraj.dhar@epfl.ch | Switzerland | Ecole Polytechnique Federale de Lausanne | 20 years experience working with Mycobacterium tuberculosis, antibiotics, single-cell imaging, host-pathogen interactions. |
| NOELIA | ALONSO RODRIGUEZ | noelialonsor@gmail.com | Norway | University of Oslo | In vitro activity of new drugs against Mtb and other mycobacteria. Macrophage Mtb infection model. Zebrafish in vivo model |
| Olga | Genilloud | olga.genilloud@medinaandalucia.es | Spain | Fundacion MEDINA | Previous experience as member of ND4BB ENABLE Platform; HTS and Preclinical Development Platforms for new Antibiotic Discovery |
| Kristina | Orrling | Orrling@yahoo.se | Netherlands | Lygature | Project coordination, call recruitment and reviewing processes, regulatory innovation, public/patient involvement |
| Claudia | Pfander | pfander@arttic.eu | France | ARTTIC | Project Management Services with focus on IMI2, Dissemination |
| Paula | Garcia | pgarcian@idibell.cat | Spain | Bellvitge Biomedical Research Institut | |

| | | | | | |
|-----------|----------------|------------------------------------|---------------|--|--|
| Philip | Gibbon | philip.gibbon@ime.fraunhofer.de | Germany | Fraunhofer | Fraunhofer developed the ND4BB InfoCentre and would bring this platform and know-how related to data and knowledge management |
| Rafael | Prados-Rosales | pradosrosales@gmail.com | Spain | Universidad Autonoma de Madrid | microbiology, immunology, screening approaches, novel mechanisms, phenotypic screening |
| Peter | Sander | psander@imm.uzh.ch | Switzerland | University of Zurich | BSL3 laboratory, 25 years of experience working with mycobacteria (M.tb), recent TB-drug screen (400 000 compounds) |
| Remko | van Leeuwen | r.vanleeuwen@aighd.org | Netherlands | AIGHD | |
| Rajesh | Gupta | rajesh.gupta@otsuka-us.com | United States | Otsuka | |
| Remco | de Vruh | remco.devruh@lygature.org | Netherlands | Lygature | Expertise in managing large public-private research programs, including appropriate financial, communication and legal support |
| Rene | Coppens | rene.coppens@tbvi.eu | Netherlands | TuBerculosis Vaccine Initiative | Scientific coordination / Project management |
| Richard | Liwski | rliwski@c-path.org | United States | Critical Path Institute | C-Path's Data Collaboration Center works with CPTR to host a large data platform for sharing of TB clinical trial data |
| Rosario | Musumeci | rosario.musumeci@unimib.it | Italy | University of Milano-Bicocca | Newly patented, in vitro active compounds against multidrug resistant bacteria |
| Viviana | Roman | rviviana30@yahoo.com | Romania | Institute of Virology- Center of Immunology | |
| Sandeep | Ghorpade | sandeep.ghorpade@uct.ac.za | South Africa | University of Cape Town | |
| Santiago | Ramon Garcia | santiramon@unizar.es | Spain | Research & Development Agency of Aragon (ARAID) Foundation | Drug profiling, combination studies, in vitro and in vivo models, PKPD modeling, MoA elucidation studies, time-lapse microscopy |
| Sandra | Pla | spla@synapse-managers.com | Spain | SYNAPSE RESEARCH MANAGEMENT PARTNERS, S.L. | Project Management |
| Şükran | Alpdemir | sukran.alpdemir@tubitak.gov.tr | Turkey | TÜBİTAK | |
| Sara | Vicente | svicenteo@ibecbarcelona.eu | Spain | Institute for Bioengineering of Catalonia (IBEC) | Molecular mechanisms of bacterial infections/biofilms, identify antibacterial molecules/targets; nanomedic. applied to microbiol |
| Tanya | Parish | tanya.parish@idri.org | United States | Infectious Disease Research Institute | Tuberculosis drug discovery expertise, mycobacterial research expertise |
| Tom | Vercruysse | tom.vercruysse@kuleuven.be | Belgium | KU Leuven | |
| Ursula | Bilitewski | ursula.bilitewski@helmholtz-hzi.de | Germany | Helmholtz Centre for Infection Research | Drug screening, microbiology, access to omic-technologies, assay development |
| Monica | Vazquez-Moreno | vazquez_monmor@gva.es | Spain | FISABIO | Expertise in IMI projects coordination on vaccine development |
| Veronique | Dartois | veronique.dartois@rutgers.edu | United States | Rutgers University | |
| Klaus | Romero | vfortin@c-path.org | United States | Critical Path Institute | Clinical Pharmacology and Quantitative Medicine expertise |
| Ferenc | Weigl | weigl.ferenc@aek.hu | Hungary | National Healthcare Services Centre | |
| Wim-Jan | Koot | wim-jan.koot@lygature.org | Netherlands | Lygature | Project/Partnership Management, Data Management, Regulatory Expertise, Patient Engagement (in short:partnership infrastructure) |